Tumorigenicity and genetic profiling of circulating tumor cells in small-cell lung cancer

Small-cell lung cancer (SCLC), an aggressive neuroendocrine tumor with early dissemination and dismal prognosis, accounts for 15–20% of lung cancer cases and ∼200,000 deaths each year. Most cases are inoperable, and biopsies to investigate SCLC biology are rarely obtainable. Circulating tumor cells (CTCs), which are prevalent in SCLC, present a readily accessible 'liquid biopsy'. Here we show that CTCs from patients with either chemosensitive or chemorefractory SCLC are tumorigenic in immune-compromised mice, and the resultant CTC-derived explants (CDXs) mirror the donor patient's response to platinum and etoposide chemotherapy. Genomic analysis of isolated CTCs revealed considerable similarity to the corresponding CDX. Most marked differences were observed between CDXs from patients with different clinical outcomes. These data demonstrate that CTC molecular analysis via serial blood sampling could facilitate delivery of personalized medicine for SCLC. CDXs are readily passaged, and these unique mouse models provide tractable systems for therapy testing and understanding drug resistance mechanisms.

[1]  R. Livingston,et al.  Improved chemotherapy for small-cell undifferentiated lung cancer. , 1976, JAMA.

[2]  Emmanuel Barillot,et al.  Control-free calling of copy number alterations in deep-sequencing data using GC-content normalization , 2010, Bioinform..

[3]  S. Schwartz,et al.  Prostate cancer and other xenografts from cells in peripheral blood of patients. , 2000, Cancer research.

[4]  C. Belani,et al.  Small-cell lung cancer: an update on targeted therapies. , 2013, Advances in experimental medicine and biology.

[5]  C. Swanton.  Intratumor heterogeneity: evolution through space and time. , 2012, Cancer research.

[6]  R. Davenport.  Diagnostic value of crush artifact in cytologic specimens. Occurrence in small cell carcinoma of the lung. , 1990, Acta cytologica.

[7]  M. Poupon,et al.  Response of small-cell lung cancer xenografts to chemotherapy: multidrug resistance and direct clinical correlates. , 1993, Journal of the National Cancer Institute.

[8]  J. Minna,et al.  Establishment of continuous, clonable cultures of small-cell carcinoma of lung which have amine precursor uptake and decarboxylation cell properties. , 1980, Cancer research.

[9]  B. Horsthemke,et al.  Identification of RB1 germline mutations in Argentinian families with sporadic bilateral retinoblastoma. , 1995, Journal of medical genetics.

[10]  Giovanni Parmigiani,et al.  A primary xenograft model of small-cell lung cancer reveals irreversible changes in gene expression imposed by culture in vitro. , 2009, Cancer research.

[11]  N. Stoecklein,et al.  Genetic heterogeneity of single disseminated tumour cells in minimal residual cancer , 2002, The Lancet.

[12]  Wainer Zoli,et al.  Detection and recovery of circulating colon cancer cells using a dielectrophoresis-based device: KRAS mutation status in pure CTCs. , 2013, Cancer letters.

[13]  H. Hakonarson,et al.  ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data , 2010, Nucleic acids research.

[14]  Daniel F. Hayes,et al.  Analysis of Circulating Tumor DNA to Monitor Metastatic Breast Cancer , 2013 .

[15]  M. DePristo,et al.  The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. , 2010, Genome research.

[16]  Y. Shimosato,et al.  A new floating cell line derived from human pulmonary carcinoma of oat cell type. , 1971, Gan.

[17]  G. T. Budd,et al.  Circulating Tumor Cells at Each Follow-up Time Point during Therapy of Metastatic Breast Cancer Patients Predict Progression-Free and Overall Survival , 2006, Clinical Cancer Research.

[18]  K. Cibulskis,et al.  Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer , 2012, Nature Genetics.

[19]  Tim Holland-Letz,et al.  Identification of a population of blood circulating tumor cells from breast cancer patients that initiates metastasis in a xenograft assay , 2013, Nature Biotechnology.

[20]  Jonathan W. Uhr,et al.  Tumor Cells Circulate in the Peripheral Blood of All Major Carcinomas but not in Healthy Subjects or Patients With Nonmalignant Diseases , 2004, Clinical Cancer Research.

[21]  B. Lorenz,et al.  Constitutional RB1-gene mutations in patients with isolated unilateral retinoblastoma. , 1997, American journal of human genetics.

[22]  Z. Szallasi,et al.  Parallel evolution of tumour subclones mimics diversity between tumours , 2013, The Journal of pathology.

[23]  F. Rojo,et al.  Genetic changes in small cell lung carcinoma , 2008, Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico.

[24]  M. Ychou,et al.  Origin and quantification of circulating DNA in mice with human colorectal cancer xenografts , 2010, Nucleic acids research.

[25]  A. Fersht,et al.  The tumor suppressor p53: from structures to drug discovery. , 2010, Cold Spring Harbor perspectives in biology.

[26]  E. Birney,et al.  A small cell lung cancer genome reports complex tobacco exposure signatures , 2009, Nature.

[27]  M. DePristo,et al.  A framework for variation discovery and genotyping using next-generation DNA sequencing data , 2011, Nature Genetics.

[28]  Peter Ulz,et al.  Complex tumor genomes inferred from single circulating tumor cells by array-CGH and next-generation sequencing. , 2013, Cancer research.

[29]  D. Osoba,et al.  VP‐16 alone and in combination with cisplatin in previously treated patients with small cell lung cancer , 1984, Cancer.

[30]  K. Pienta,et al.  Circulating Tumor Cells Predict Survival Benefit from Treatment in Metastatic Castration-Resistant Prostate Cancer , 2008, Clinical Cancer Research.

[31]  R. Wittes,et al.  cis-Dichlorodiammineplatinum(II) and VP-16-213: an active induction regimen for small cell carcinoma of the lung. , 1979, Cancer treatment reports.

[32]  D. Osoba,et al.  VP-16 and cisplatin as first-line therapy for small-cell lung cancer. , 1985, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  M. Hidalgo,et al.  Prioritizing phase I treatment options through preclinical testing on personalized tumorgraft. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  Rudolf M. Huber,et al.  Combined transcriptome and genome analysis of single micrometastatic cells , 2002, Nature Biotechnology.

[35]  J. Minna,et al.  Molecular genetics of small cell lung carcinoma. , 2001, Seminars in oncology.

[36]  Caroline Dive,et al.  Clinical significance and molecular characteristics of circulating tumor cells and circulating tumor microemboli in patients with small-cell lung cancer. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[37]  Caroline Dive,et al.  Molecular analysis of circulating tumour cells—biology and biomarkers , 2014, Nature Reviews Clinical Oncology.

[38]  Caroline Dive,et al.  Evaluation and prognostic significance of circulating tumor cells in patients with non-small-cell lung cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[39]  A. Berns,et al.  Mouse models for lung cancer , 2013, Molecular oncology.

[40]  Michal J. Okoniewski,et al.  X:Map: annotation and visualization of genome structure for Affymetrix exon array analysis , 2007, Nucleic Acids Res..

[41]  A. Sieuwerts,et al.  Semiautomated isolation and molecular characterisation of single or highly purified tumour cells from CellSearch enriched blood samples using dielectrophoretic cell sorting , 2013, British Journal of Cancer.

[42]  W. William,et al.  Novel strategies for the treatment of small-cell lung carcinoma , 2011, Nature Reviews Clinical Oncology.

[43]  Bert Vogelstein,et al.  DETECTION OF CIRCULATING TUMOR DNA IN EARLY AND LATE STAGE HUMAN MALIGNANCIES , 2014 .

[44]  X. Xie,et al.  Reproducible copy number variation patterns among single circulating tumor cells of lung cancer patients , 2013, Proceedings of the National Academy of Sciences.

[45]  M. Hollingshead,et al.  Real-time PCR-based assay to quantify the relative amount of human and mouse tissue present in tumor xenografts , 2011, BMC biotechnology.

[46]  J. Izbicki,et al.  Heterogeneity of epidermal growth factor receptor status and mutations of KRAS/PIK3CA in circulating tumor cells of patients with colorectal cancer. , 2013, Clinical chemistry.

[47]  A. Berns,et al.  Induction of small cell lung cancer by somatic inactivation of both Trp53 and Rb1 in a conditional mouse model. , 2003, Cancer cell.

[48]  Steven J. M. Jones,et al.  Circos: an information aesthetic for comparative genomics. , 2009, Genome research.

[49]  Caroline Dive,et al.  Tumorigenesis and Neoplastic Progression Evaluation of Circulating Tumor Cells and Serological Cell Death Biomarkers in Small Cell Lung Cancer Patients Undergoing Chemotherapy , 2010 .

[50]  M. Choti,et al.  Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies , 2014, Science Translational Medicine.

[51]  M. Cristofanilli.  Circulating tumor cells, disease progression, and survival in metastatic breast cancer. , 2006, Seminars in oncology.

[52]  Robert Gentleman,et al.  Comprehensive genomic analysis identifies SOX2 as a frequently amplified gene in small-cell lung cancer , 2012, Nature Genetics.

[53]  C. Klein.  Selection and adaptation during metastatic cancer progression , 2013, Nature.

[54]  M. Ranson,et al.  Isolation and Extraction of Circulating Tumor DNA from Patients with Small Cell Lung Cancer , 2008, Annals of the New York Academy of Sciences.

[55]  A. Okamoto,et al.  Variable mutations of the RB gene in small-cell lung carcinoma. , 1990, Oncogene.